Brefeldin A

Catalog No.S7046

Brefeldin A  Chemical Structure

Molecular Weight(MW): 280.36

Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis.

Size Price Stock Quantity  
In DMSO USD 80 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

1 Customer Review

  • J Biol Chem, 2014, 289(32):22284-305.. Brefeldin A purchased from Selleck.

Purity & Quality Control

Choose Selective ATPase Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis.
Targets
ATPase (HCT 116) [1]
0.2 μM
In vitro

Brefeldin A is a fungal metabolite and blocks the forward transport between the endoplasmic reticulum and Golgi apparatus, Brefeldin A causes an impaired distribution of the membrane proteins. When HCT 116 human colon cancer cell is treated with Brefeldin A, morphological changes indicating cell differentiation are observed. Brefeldin A exerts its cytotoxic effects mainly by inducing differentiation and apoptosis in tumor cells. [1] The treatment of the strips with 20 μg/mL Brefeldin A for 6 hours completely abolishes the relaxation induced by bradykinin in the presence of 10mM indomethacin and 30 μM L-NOARG. The treatment with 20 μg/mL Brefeldin A substantially abolishes the bradykinin-induced decreases in [Ca2+]i and tension in the range of concentrations between 1 nM and 1 mM. Brefeldin A has no effect on the [Ca2+]i elevation in endothelial cells induced by bradykinin or substance P. [2] Addition of the fungal metabolite Brefeldin A does not affect the spontaneous phospholipid-dependent GTPS binding to myr-rARF1 but totally abolishs the retinal isotonic extract (RIE)-catalyzed exchange, with half-maximal inhibition at 2 μM Brefeldin A. Brefeldin A prevents a wide variety of membrane traffic pathways. Brefeldin A inhibits an ADP-ribosylation factor-specific guanine nucleotide exchange activity present in Golgi membranes or in brain cytosol. The complete prevention by Brefeldin A strongly suggests that the retinal extract contains an ARF-specific guanine nucleotide exchange factor. Retinal isotonic extract (RIE)-catalyzed GTPS release from both ADP-ribosylation factors (ARFs) is only partly inhibited by Brefeldin A, even at 300 μM. [3] Brefeldin A induces fusion of the Golgi apparatus with the ER. Brefeldin A abolishes the inhibitory effect of the CERT inhibitor HPA-12. Brefeldin A treatment, which induces fusion of the Golgi apparatus and the ER, rescues the limonoid-induced prevention of sphingomyelin biosynthesis. BFA treatment of CHO cells causes a 2 to 3 fold increase in sphingomyelin synthesis. [4] Apart from B-CLL cells, Brefeldin A reportedly causes apoptosis in multiple myeloma (U266, NCI-H929), Jurkat, HeLa, leukaemia (HL60, K562, BJAB), colon (HT-29) and prostate, as well as adenoid cystic sarcoma cells. The administration of 25 ng/mL of Brefeldin A completely blocks growth of HF4.9 and HF28RA cells, whereas higher Brefeldin A doses (75 ng/mL) are required to achieve the same effect in HF1A3 cells. Cell proliferation is inhibited within 24 hours in a dose-dependent manner and, depending on the cell line, almost complete cessation of 3H-thymdine incorporation is observed at 50-75 ng/mL of Brefeldin A (26%, 76%, 87% inhibition at 50 ng/ml and 75%, 87%, 92% inhibition at 75 ng/mL for HF1A3, HF4.9 and HF28RA cells respectively. Brefeldin A-induced cell killing is in a dose-dependent manner using YO-PRO 1/PI assay. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
PC12 NHO4UXFHfW6ldHnvckBCe3OjeR?= MoPQNkDPxE1? NXfmbHk{OSCq MYnpcohq[mm2czD0bIUhVC2GT2DBJEgzOMLizszNLU1qdmS3Y3XkJJRz[W6|aXXueEBGWktzL{KgdIhwe3Cqb4L5cIF1cW:wwrC= NULuO2ltOjZ|NkOxPVE>
C2C12 MnzZSpVv[3Srb36gRZN{[Xl? NEP2eGMyyqEQvHevcYw> MorLNeKhcA>? MXPhZo9tcXOqZYOgZ5l1d2urbnWgdoVt\WG|ZTDmdo9uKEN{Q{GyJI16d3S3YnXz M4\1e|I3OjlzMke5
MEFs WT NX3wfFJnTnWwY4Tpc44hSXO|YYm= MmrROeKh|ryP Ml\uNlAhdWmw MYjjZZV{\XNicnXzbYRmdnRiZX76fY1meyC|dXPoJIF{KE6DR2StS2ZRNCC2bzDkbYZnfXOnIHLhZ4shfG9idHjlJGVT MYSyOlE6PjB{Mx?=
MEFs VAMP7 KO NVfVWm1HTnWwY4Tpc44hSXO|YYm= M1PvUlXDqM7:TR?= NWLBZYhQOjBibXnu MnPSZ4F2e2W|IILld4ll\W62IHXufplu\XNic4XjbEBieyCQQVfUMWdHWCxidH:g[Iln\nW|ZTDiZYNsKHSxIITo[UBGWg>? NIKxVGUzPjF7NkCyNy=>
SMCs NVn5THFxTnWwY4Tpc44hSXO|YYm= NFrRfosyOMLiwsXnM41t M3LxblAuOTJiaB?= MnT2SG1UVw>? NYD4VW97e2ixd4OgZUB1emWwZDD0c5diemS|IHGgbIlocGW{IHPvcoNmdnS{YYTpc44hd2ZidHjlJGVTN1OUIH7leJdwemtiaX6geIhmKHCncnnueYNt\WG{IHHy[YHDqA>? M1TiRlI3OTd{MEiw
SMCs MVLGeY5kfGmxbjDBd5NigQ>? MYSxNOKhyrWpL33s NVPve2g2OC1zMjDo NWjpWVdKTE2VTx?= MlXlZ4F2e2W|IHGgeJJidnOrZX70JGNiOiwEoILlcIVie2ViZoLvcUB1cGViRWKvV3LDqA>? MUWyOlE4OjB6MB?=
HEMC-1 MoP1SpVv[3Srb36gRZN{[Xl? M{\3c|AvOcLiwsXnM41t NFnpSG8zPMLiaB?= MWXjZZV{\XNiYTDobYdp\XJiaX7obYJqfG:{eTDl[oZm[3Rib36g[Zhw[3m2b4Ppd{B1cGGwIH7vZ49l[XqxbHW= MlvDNlU6PzJ5NUm=
HUVEC MkOzSpVv[3Srb36gRZN{[Xl? M{\GdVExyqEQvF2= MXexxsBp NICyPJhFVVOR MYfhZo9tcXOqZYOgbJlxd3irYT3pcoR2[2WmIILlcIVie2Vib3[gRXRRKG[{b32gZZBq[2GuIHHu[EBj[XOxbHH0[ZJidCC|dYLmZYNmew>? NHXJe3czPTl3Nkm4PC=>
HUVEC NI[1TopHfW6ldHnvckBCe3OjeR?= M3TxOVExyqEQvF2= NUDXWIxwOcLiaB?= M{\PdGROW09? MYnpcoNz\WG|ZYRCpJRp\SCwdX3i[ZIh[W6mIHnueIVve2m2eTDv[kBndHWxcnXzZ4VvfCCjcnXhd{Bme3CnY3nhcIx6KGmwIIDldolvfWOuZXHyJJNx[WOn NWHIZmkyOjV7NU[5PFg>
Caco-2 NWDMVY9{TnWwY4Tpc44hSXO|YYm= MkGyNk42KM7:TR?= Mn3MN|AhdWmw NH;ESohifHSnboXheIV{KHSqZTDUS2Yu|rJzLX3l[IlifGWmIHnuZ5Jm[XOnIHnuJHNGWlRiZoXuZ5Rqd25? MVeyOVk2PDl|MR?=
NRK MVjGeY5kfGmxbjDBd5NigQ>? NF7xT5gzODEkgJXu[{9udA>? NVf1OGpWPOLChXi= MWXEUXNQ M4nNNpJme2O3ZYOgcYl1d3SrYzDwdo9oemW|c3nvci=> M{\OWFI2QTR6NUi2
HeLa NHLoN2tHfW6ldHnvckBCe3OjeR?= NUjjd5JxOjBy4pEFcocwdWx? M{HaXlMhcA>? MXHEUXNQ NFnjdGpqdmS3Y3XzJJRp\SCjcoTp[olkcWGuIHLy[YFsNXWyIH;mJJRp\SCJb3znbUBkd22ybHX4 MYOyOVk1QDV6Nh?=
COS MlHqSpVv[3Srb36gRZN{[Xl? MWmxJO69\y:vbB?= Mk\tN{Bp MXXjc41xdGW2ZXz5JIRqe3CncoPld{B1cGViQWCtNUB{cWewYX|CpC=> NYXDSHJnOjV7MUW5NFA>
DF1  MoC5SpVv[3Srb36gRZN{[Xl? NHHoUJMyyqEQvF5CpC=> MVy0PEBp M3\WPGROW09? MXrkbZNx\XK|ZYRCpJRp\SCneH;n[Y5wfXNiQ2PHZYxPSWOWMjDwdo91\Wmw MljxNlU5ODdyNUS=
nHDFs  M1jvTmZ2dmO2aX;uJGF{e2G7 NHG0[XYyyqEQvF5CpC=> NU[ySpplOsLiaB?= M3\Le5Bz\X[nboTzJJRp\SCjc4PlcYJtgSCxZjDjfZRwe2:uaXOgZ49ifCCycn;0[YlveyCxboTvJGdwdGerIH3lcYJz[W6ncx?= MmXjNlU4PzJ4MU[=
FRT  M3nqcmZ2dmO2aX;uJGF{e2G7 MVu1JO69\y:vbB?= MXyyxsBp M1Xk[YJtd2OtczD0doFn\mmla3nu[{B1cHKxdXfoJJRp\SCJb3znbUBkd22ybHX4JIJ6KGmwaHnibZRqdmdiRWKteI8uT2:uZ3mgeJJidnOyb4L0 NX;6XYxkOjV5NkexNVU>
FRT  NYXtNIVHTnWwY4Tpc44hSXO|YYm= M33UZlUh|rypL33s NXHueIJOOsLiaB?= MXvwdoV3\W62czD0bIUhcW6lcnXhd4UhcW5iY3zlZZZm\CEQsTDzeYJ2dmm2czD3bIVvKFuQYTvdbeKhf2G|IILl[JVk\WR? NEHsd2ozPTd4N{GxOS=>
HepG2  M1v5TGZ2dmO2aX;uJGF{e2G7 NYKxOW46OeLCidM1UeKh MnXaNlQhcA>? MofkSG1UVw>? NHXkcmRl\WO{ZXHz[ZMhfGinIHzleoVtKG:oIGDYVkBuWk6D MkTsNlU3OTZ3OUe=
SMCs NVXONIZKTnWwY4Tpc44hSXO|YYm= NYDBb|A5Oc7:Zz;tUC=> M3n5cVMhcA>? NFXRN4hi[2O3bYXsZZRmeyCFTmDZNkBxem:2ZXnuJIlvKHSqZTDFVkBkd22yYYL0cYVvfCCjbnSgco8hdG:wZ3XyJINwNWyxY3HsbZpm\CC5aYToJJRp\SCJb3znbUBu[XKtZYNCpC=> MWOyOVU5QTR{NR?=
OB-6 MnPPRZBweHSxc3nzJGF{e2G7 MX2yMlfDqM7:TR?= NFK3V3g1QCCq M2PXOYlv\HWlZYOgZZBweHSxc3nz NIG2UmYzPTV|MkS4NC=>
iPSC-CMs  NV;FXIJJTnWwY4Tpc44hSXO|YYm= M{OyflUxOCCwZz;tcC=> NUHZXYhsPDhiaB?= MmO2bY5kemWjc3XzJJRp\SCrboTlcpNqfHlib3[geIhmKGirZ3jldkBud2KrbHn0fUBNSU2SczDheEB1cGViY3;zeEBw\iC2aHWgcI94\XJibX;ibYxqfHlic4DlZ4lmew>? M3jrTVI2PDh6Nk[2
SP-Nluc NYLQ[pp4TnWwY4Tpc44hSXO|YYm= NIXIb3Q2KG2pL33M MojWOkBp MoTuSG1UV8Li NYTBRVND[2G3c3XzJIFvKGmwY4LlZZNmKGmwIILldI9zfGW{IHHjeIl3cXS7IHnuJJRp\SCyYYLhd4l1\Q>? M1y3SVI2Ozl{OUm4
PEXEL-Nluc M{TZemZ2dmO2aX;uJGF{e2G7 Mmq0OUBu\y:vTB?= NIDXSoY3KGh? NWPFWJRiTE2VT9Mg MYTjZZV{\XNiYX6gbY5kemWjc3WgbY4hemWyb4L0[ZIh[WO2aY\peJkhcW5idHjlJJBiemG|aYTl NFrXRWczPTN7Mkm5PC=>
H1299 NVPxOY9XTnWwY4Tpc44hSXO|YYm= M2q3blExKM7:Zz;tcC=> NHzlNFEzPCCq MnzLbY5lfWOnczDheZRweGijZ4pCpC=> MUGyOVM5QDl5MB?=
MDA-MB-231 M1GyWmNmdGxiVnnhZoltcXS7IFHzd4F6 MVyw5qCUPTBizsznM41N NEHxbmk1QCCq M3ezbWVEPTEEoE2gNE4xOTZiwsXnM41N Mo\rNlU{PTZ3Nke=
MDA-MB-231 NILsTnhCeG:ydH;zbZMhSXO|YYm= MUSwMlEh|rypL33M MWG0JIg> MUTpcoR2[2W|IHHwc5B1d3Orcx?= NXPXZZZoOjV|NU[1Olc>
MDA-MB-231 M4TwdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\pNE4xOS9yLkC1JO69\y:vTB?= MojkNlQhcA>? NV3aS4NEcW6lcnXhd4V{KHSqZTDmdoFkfGmxbjDv[kB{fWJvR{GgZ4VtdCCmZXLybZM> MUCyOVM2PjV4Nx?=
MDA-MB-231 NWnNPHlTSXCxcITvd4l{KEG|c3H5 M1;XcFAvODYkgKOxJO69\y:vTB?= Mm[3NlQhcA>? NETERWRqdmS3Y3XzJHBCWlBiKIDvcJkhSUSSLYLpZo9{\SCyb3z5cYVz[XOnLUGpJINt\WG4YXfl MoCwNlU{PTZ3Nke=
MDA-MB-231 M3jl[GZ2dmO2aX;uJGF{e2G7 M13kfVDjiJN3MDFOwIcwdUx? MX2yOEBp MXrpcohq[mm2czD0bIUh\m:{bXH0bY9vKG:oIEPEJIFv\CB{RDDjc4xwdmmncx?= MVyyOVM2PjV4Nx?=
A172 MYfGeY5kfGmxbjDBd5NigQ>? NWr5d4NJOTEEoN88[{9udA>? M2fpb|TDqGh? MnXQSG1UV8Li NUnZNJVjemW|dXz0d{BqdiC2aHWgdoV1em:pcnHk[UB1emGwc4DvdpQhd2ZiZnz1c5Jme2OnboSg[5JidnWuZYO= MWmyOVI{QTVyNx?=
KMS-6 MXrGeY5kfGmxbjDBd5NigQ>? NVTZRZZrOcLizszNxsA> NX:xSWg1OjRiaB?= NIq3Z5RmgGirYnn0d{Bp[WyoIITo[UB{\WO{ZYTpc44hd2ZiZ3HsZY5qdi2OSTDhd{BlcWRidHjlJINwdnS{b3y= M1vrcVI2OjJ7MUK2
MEC Mk\5SpVv[3Srb36gRZN{[Xl? M3v6[FEh|ryP MmHTNU42KGh? M3j6O4NifXOnczDhJIRz[W2jdHnjJIRm[3KnYYPlJIlvKHSqZTDzeZJn[WOnIG\FS2ZTOg>? MofHNlUzOjh6MUW=
HEK293/hERG MoXiSpVv[3Srb36gRZN{[Xl? M1q1[lExyqEQvF2= NGi0UXIyyqCq NYCxXZFZemW|dXz0d{BqdiCjIITpcYUu\GWyZX7k[Y51KHKnZIXjeIlwdiCvYYT1doUhcEWURzDwdo91\WmwwrC= MkW4NlUzOTh2Nkm=
RBE4 NH\5e2VCeG:ydH;zbZMhSXO|YYm= MXWyxsDPxE1? NFXNZ3Y{6oDVMkVCpIg> NXLi[YZqcW6mdXPld{BieG:ydH;zbZMhfGmvZTDk[ZBmdmSnboTsfS=> NEL0O5IzPTF{OECyOS=>
RBE4 NF[xNVdHfW6ldHnvckBCe3OjeR?= MlfoNuKh|ryP Mn\wN-KBmzJ2wrDo NYjvXmlLcW6lcnXhd4V{KHSqZTDYRnAyKHC{b4TlbY4hdGW4ZXzzJIFnfGW{IEOgZY5lKDcEoHigc4YhfHKnYYTt[Y51 NV7OOo9rOjVzMkiwNlU>
RBE4 MVnGeY5kfGmxbjDBd5NigQ>? NFL1RpgzyqEQvF2= NYD6VWdsO+LCk{K0xsBp MnPzbY5kemWjc3XzJIFkfGm4ZTDjZZNx[XOnLUGyJIlvKGFidHnt[U1l\XCnbnTlcpQhdWGwbnXyxsA> NFrtSm8zPTF{OECyOS=>
RBE4 MUPGeY5kfGmxbjDBd5NigQ>? MYeyxsDPxE1? NVftVYhJO+LCk{K0xsBp M1XQcIlv[3KnYYPld{B1cGVibHX2[Yx{KG:oIGLPV{B1cW2nLXTldIVv\GWwdHz5 MWqyOVEzQDB{NR?=
RBE4 NXTBcoxyTnWwY4Tpc44hSXO|YYm= NWrjW5RUOsLizszN NGflVZM{6oDVMkVCpIg> Mnf4bY5lfWOnczDhJIRmdGG7ZXSg[IVxdGW2aX;uJI9nKHSqZTDFVkBE[TJtwrDjc451\W62IHH0JFbDqGhib3[gbY5kfWKjdHnvckB{cWewaX\pZ4FvfGy7 NVXCV25jOjVzMkiwNlU>
RBE4 Mn7YSpVv[3Srb36gRZN{[Xl? M2LCPFLDqM7:TR?= M{nxNVPjiJN{NNMgbC=> NX\3SoRicW6mdXPld{BidiCxdnXycI9i\CCxZjDDZVIsyqCrbjD0bIUhdWm2b3Poc45lemmjIHnuJJRp\SCoaYLzeEA3yqCqIH;mJIlv[3WkYYTpc44hMHEkgJm85qCKOC5yMEGpJIJ2fCCFYUKrxsBt\X[nbIOgbY4hfGirczDvdodidmWubHWg[IVkemWjc3XkJIFnfGW{IEGyxsBpKG:oIHnuZ5Vj[XSrb36= NHXhO4szPTF{OECyOS=>
Huh-7  MX7GeY5kfGmxbjDBd5NigQ>? Ml3DNe69\y:vTB?= MmHwN-KBmzJ2wrDo M{\xdYlv[3KnYYPld{B1cGVibHX2[Ywhd2ZiQWDFNUBqdiCjIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> M3r1SlI2ODJ4MUe0
HepG2  M2PsOmZ2dmO2aX;uJGF{e2G7 M4K4dlHPxGdxbVy= MViz5qCUOjUEoHi= MVvpcoNz\WG|ZYOgeIhmKGyndnXsJI9nKEGSRUGgbY4h[SC2aX3lMYRmeGWwZHXueEBu[W6wZYK= MljvNlUxOjZzN{S=
H838-LKB1 MWPGeY5kfGmxbjDBd5NigQ>? Ml71N|DDqG6pL33s MWWxNk8yQCCq MUjpcoNz\WG|ZYOgeIhmKHC{b4TlbY4hdGW4ZXzzJI9nKEKrUNMg NHvWSlMzPTBzMUC4Ni=>
H838-KDLKB1  NW\tVJlZTnWwY4Tpc44hSXO|YYm= NIjiPZQ{OMLibnevcYw> NYLURoRLOTJxMUigbC=> NWSwWnBzcW6lcnXhd4V{KHSqZTDwdo91\WmwIHzleoVteyCxZjDCbXDDqA>? MmO0NlUxOTFyOEK=
H838-KDLKB1  NX76OG9UTnWwY4Tpc44hSXO|YYm= Mn\IN|DDqG6pL33s MmrINVIwOThiaB?= M3;Ze4lv[3KnYYPld{B1cGVibHX2[Yx{KG:oIIDoc5NxcG:{eXzheIVlKGWLRkNOtUApeGixc4Doc{1mUUZ{zsGp M3\xUVI2ODFzMEiy
3T3-L1 NHzNbmpHfW6ldHnvckBCe3OjeR?= NGPVdog2KM7:Zz;tcC=> MX:zNEBucW5? MmD2cYlucWO|IITo[UBm\m[nY4TzJI9nKGmwc4XsbY4h[W6mIHPheZNmeyC{b3L1d5QheGixc4Doc5J6dGG2aX;uJI9nKEGtdDCoV4VzKDR5MzmgZY5lKHCqb4PwbI9zgWyjdHnvckBw\iCDU{G2NEApXGi{IE[0NkBidmRiU3XyJFU5QCl? M1fzcVI1QDR|OEK3
3T3-L1 MW\GeY5kfGmxbjDBd5NigQ>? NIfxVXI2KM7:Zz;tcC=> MU[zNEBucW5? MkG1doVk[XCrdIXsZZRmeyCrboP1cIlvKGGldHnvckB4cXSqIILld5Bm[3RidH:gdoVofWyjdHnu[{BCc3RiYXP0bZZqfHliYX7kJGFUOTZyIIDoc5NxcG:{eXzheIlwdg>? MU[yOFg1Ozh{Nx?=
3T3-L1 MY\GeY5kfGmxbjDBd5NigQ>? NYDrW5A{PSEQvHevcYw> NFTYZpE{OCCvaX6= NXjiN2lQ[2G3c3XzJJJmfmW{c3nicIUhemWmaYP0doljfXSrb36gc4YhT0yXVES= NH3jbFczPDh2M{iyOy=>
3T3-L1 NEP2dopHfW6ldHnvckBCe3OjeR?= Mk[4OUDPxGdxbXy= MonNNeKhcA>? NXrlcmhE[2G3c3XzJJJm\Gm|dILpZpV1cW:wIH;mJGdNXVR2IHL1eEBvd3RiaX7jdoVie2ViaX6g[4x2[2:|ZTD1dJRic2V? MVeyOFg1Ozh{Nx?=
3T3-L1 NXnxfVkxTnWwY4Tpc44hSXO|YYm= NXvsSlhDPSEQvHevcYw> Mlf6NeKhcA>? MojZZ4F2e2W|IIDoc5NxcG:{eXzheIlwdiCxZjD0bIUhTm:6T{GgeJJidnOlcnnweIlwdiCoYXP0c5I> MlTSNlQ5PDN6Mke=
HeLa  M17sdWZ2dmO2aX;uJGF{e2G7 M4HuW|Uh|rypL33s Mlf6N{Bp MnPjZ4F2e2W|IH71Z4xm[XJiZYjjcJV{cW:wIH;mJJRp\SCIb4jPNUB1emGwc3PybZB1cW:wIH\hZ5RweiCjbnSg[IVkemWjc3XzJJRz[W6|Y4LpdJRqd25ib3[gSo95VzFvcnXneYxifGWmIHflcoV{ NIDI[W8zPDh2M{iyOy=>
HEK293 M131c2Z2dmO2aX;uJGF{e2G7 NIDDOVc2yqEQvHevcYw> NF7mdnAyOsLiaB?= MlLsZYJwdGm|aHXzJGNOSS2rbnT1Z4VlKEOURVzENkB{\WO{ZYTpc44> NVjGRpA{OjR4OEe0N|E>
COS-1 NXS1TnJqTnWwY4Tpc44hSXO|YYm= MofLOUDDvWdxbXy= NH6zbpgzPCCqwrC= NH;YOVRz\XO2cnnjeJMhdG:lYXzpfoF1cW:wIH;mJG5DKGmwIITo[UBx\XKrboXjcIVieiC{ZXfpc47DqA>? MkfHNlQ3PzF5NUG=
PRP MYnGeY5kfGmxbjDBd5NigQ>? NF7mc3YyOCEQvF2= MoD5ZYJzd2ejdHXzJHNFTi1zzsGtcYVlcWG2ZXSgR3hEWjdiZYj0[ZJv[WyrenH0bY9vyqB? M4DmblI1PjZ6N{Ww
RAW264.7 NVfLb5V[SXCxcITvd4l{KEG|c3H5 NHnoXVk1KM7:TR?= Ml7YOFghcA>? MnXJZZR1\W63YYTld{B1cGViaX7obYJqfGmxbjDv[kBwgC2ORFytbY5lfWOnZDDhdI9xfG:|aYOgZY5lKHSqZTDmZYNqdGm2YYTpc44hd2ZiY3jvcIV{fGW{b3yg[YZndHW6IHL5JGFkNWiHLUG4RU1PUDJ? Ml3kNlQ3OzlyM{K=
MDMs MnjORZBweHSxc3nzJGF{e2G7 NY\Lb|dYOTEkgJpOwIcwdWx? NXLXcodWOTJxMUWgbC=> NHyxdVhqdmS3Y3XzJIFxd3C2b4Ppdy=> NYXHVo9iOjR3NU[2PVU>
PMHs  NV:4c|B6TnWwY4Tpc44hSXO|YYm= Moi3NVDjiJN{MPMAje69\y:vbB?= NI\kPVYzPOLCiXi= MWLEUXNQ MnrxbY5lfWOnZDDFVkB{fHKnc4O= NH[5eYQzPDRyN{K0Ni=>
PMHs  MYTBdI9xfG:|aYOgRZN{[Xl? M1u2WVEx6oDVMkFihKnPxGdxbXy= MkXkNlTjiImq NH\wSWZFVVOR Mnf2bY5kemWjc3XzJINmdGxiZHXheIg> MlywNlQ1ODd{NEK=
HEK293/tau MVrGeY5kfGmxbjDBd5NigQ>? MlvaOUDPxE1? NYW5WGxzOS9{L{SgbC=> MV;pcoR2[2W|IFfvcIdqKG[{YXft[Y51[XSrb39CpC=> NXfyeJZXOjR|NkiwPFk>
HEK293/tau NEHL[lFHfW6ldHnvckBCe3OjeR?= M4i4WlUh|ryP MYKzJIg> NHfWN2FqdmS3Y3XzJJRifSCqeYDldpBpd3OyaH;yfYxifGmxbh?= MlfnNlQ{PjhyOEm=
ADF NFzFV5hHfW6ldHnvckBCe3OjeR?= M2\EcVExKM7:TR?= NIjncXMyPiCq MWXpcohq[mm2czD0bIUhYm6FbEKtbY5lfWOnZDD0doFve2yxY3H0bY9vKG:oIFPSWC=> NGDtc5ozPDJ{OEKzNi=>
U373  MVjGeY5kfGmxbjDBd5NigQ>? MWWxNEDPxE1? Mnr6NVYhcA>? MV7pcohq[mm2czD0bIUhYm6FbEKtbY5lfWOnZDD0doFve2yxY3H0bY9vKG:oIFPSWC=> M4XYOVI1OjJ6MkOy
RKO-HIPK2i NHzKTGRHfW6ldHnvckBCe3OjeR?= M2nBN|ExKM7:TR?= MXexOkBp M{S2c4lvcGmkaYTzJJRp\SCcblPsNk1qdmS3Y3XkJJRz[W6|bH;jZZRqd25ib3[gR3JV NGLuT20zPDJ{OEKzNi=>
ADF  M1TFWGZ2dmO2aX;uJGF{e2G7 Mlq0NVAh|ryPwrC= MkXtOkBp NYHDT2docW2yYXnyd{B1cGViRFOgZYN1cX[jdHnvci=> M1TjeFI1OjJ6MkOy
Huh7 M4DNfWZ2dmO2aX;uJGF{e2G7 MUi1JO69\y:vbB?= MUW0JIg> MW\hZo9tcXOqZYOgeIhmKHOnY4LleIlwdiCxZjCgbY51emGlZXzseYxieiCDcH;C MnLKNlQyODBzNEC=
Huh7 MoLPSpVv[3Srb36gRZN{[Xl? M2HtblUh|rypL33s NHX4V|gyKGh? Mn7pZ4F2e2W|IHGgd4lodmmoaXPhcpQhcW6lcnXhd4UhcW5iQYDvRk1kemW|Y3XueJM> NGjPVGczPDFyMEG0NC=>
Huh7 NVXSTHo1TnWwY4Tpc44hSXO|YYm= NILsUmw26oDVMUFCpI5oN22u Mn23NVIhcA>? MlrPbY5kemWjc3XzJGFxd0JvY4Lld4NmdnS|IIfpeIhwfXRiaX7obYJqfGmwZzDz[YNz\XSrb36= Ml63NlQyODBzNEC=
BAECs MV;GeY5kfGmxbjDBd5NigQ>? NFfCfVU2KM7:Zz;tcC=> MYWwMVQhcA>? NYDhSHRPcW6mdXPld{B1cGVicnHwbYQh\GWyaH;zdIhwenmuYYTpc44hd2ZiZV7PV{BifCCVZYKxNVc6 Mm[yNlQxQDV{MkW=
Macrophages NFL1c49HfW6ldHnvckBCe3OjeR?= MYG3NUDDvU1? MorFOkBp NWHCOJFxcW6qaXLpeJMhdHWwYYPpckBqdnSncn7hcIl7[XSrb39CpC=> M{TZNFI1ODN7N{Sw
Colo 205 M{T1NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkGyNE02KM7:Zz;tUC=> Mn32OFghcA>? MYjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiC|dYPw[Y5{cW:wIHP1cJR2emW|IIfpeIgh[W5iZYP0bY1ifGWmIFnDOVAhd2ZifkG1JI5oN22O Mlm4NlM6PzN7OU[=
Colo 205 MWLGeY5kfGmxbjDBd5NigQ>? NY\ZS5BUOC5yMUKtNE4xOjVizsznM41N NV74d|d2OTRiZB?= MVny[YR2[2W|IITo[UBkdG:wb3flcolkcXS7IH;mJGNwdG9iMkC1JGNUS3N? NXjLVZdDOjN7N{O5PVY>
Colo 205 NV3YdFhOSXCxcITvd4l{KEG|c3H5 NV:w[oR6OC5zIN88[{9uVA>? MknCNE0zPCCq NXrkR2lPcW6mdXPld{BieG:ydH;zbZMhd2ZiQ3;sc{AzODViY3XscJMhcW5ic4XzdIVve2mxbjDjeYx1fXKncx?= MmDYNlM6PzN7OU[=
Colo 205 M1LaVmZ2dmO2aX;uJGF{e2G7 MVWwMlAyPSEQvHevcWw> MojqNlQhcA>? M2DIbYlv\HWlZYOgeIhmKGW6cILld5Nqd25ib3[gSXIhe3S{ZYPzMZJmdGG2ZXSg[4Vv\XN? NHjsXJIzOzl5M{m5Oi=>
Colo 205 MYTGeY5kfGmxbjDBd5NigQ>? MXiwMlAyPSEQvHevcWw> MXGyOEBp NHvtWVVqdmirYnn0d{B1cGViYXP0bZZqfHlib3[gUW1Rew>? Mn3mNlM6PzN7OU[=
IBRS2 MofQSpVv[3Srb36gRZN{[Xl? MYK1JO69\y:vbB?= NYr2PG4{OC53IHi= MorwSG1UVw>? NF\GeVFlcXO{dYD0d{B1cGViRWLHTWMh[W6mIFfvcIdqyqB? M4GwcVI{QTZ|NUO0
IBRS2 NVfVUlFyTnWwY4Tpc44hSXO|YYm= MXq1JO69\y:vbB?= NIn5eo0xNjViaB?= NYi1bpNlTE2VTx?= M1rK[IVvcGGwY3XzJGZOTFZiaX7m[YN1cW:w M4nGOFI{QTZ|NUO0
HeLa NFLzVppHfW6ldHnvckBCe3OjeR?= MWeyJO69VQ>? MmnxNkBpyqB? NFzEOodifHSnboXheIV{KHSqZTDUUmYucW6mdXPl[EB{\WO{ZYTpc44hd2ZiSVytNVU> MWqyN|k2ODh7Mh?=
HFS  MoizSpVv[3Srb36gRZN{[Xl? MVKwMVEh|rypL33s NGXLUYozPCCq MX\HUHRRKGW6cILld5Nqd25icnXhZ4hmeyCjIIDsZZRm[XViYYSgZ49v[2WwdILheIlwdnNiYYOgcI94KGG|IECuNFEhyrWpL33s M{G1dlI{QDl2NkOz
HFS  NXjRSXc5TnWwY4Tpc44hSXO|YYm= MViwMlAyKML3Zz;tcC=> MmHMNlQhcA>? NI\XUHlqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4Yh\2y7Y3;zdIhqdmexbHnwbYQhe3mwdHjhd4Uh\2WwZYOgZZQhPiCq NWTCRlc6OjN6OUS2N|M>
OVCAR-3 NILmc3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4P0OVHjiJNzNdMg{txOyqB? MWKyOOKhcA>? MWPpcoR2[2W|IHGgcI9{eyCxZjDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6yqB? NWnWV3NUOjN6Mk[5OlQ>
OVCAR-3 M3O5NmZ2dmO2aX;uJGF{e2G7 NE\iOJEy6oDVMUZCpO69VcLi MXmyOOKhcA>? NEHFbXlqdmS3Y3XzJI52[2ynYYKg[IFu[Wen MXWyN|gzPjl4NB?=
OVCAR-3 M3PqdWFxd3C2b4Ppd{BCe3OjeR?= MkmyNU0yOMLizszN MXG0JIg> M1n6bYlv\HWlZYOgeIhmKGGldHn2ZZRqd25ib3[gZZBweHSxc3nzMZJmdGG2ZXSgdJJwfGWrboO= MmTQNlM5OjZ7NkS=
OVCAR-3 Mm\zRZBweHSxc3nzJGF{e2G7 NI\IWYgyOMLizszN NYDsSWRwOjUEoHi= MX7pcoR2[2W|IHHjeIl3[XSrb36gc4Yh[2G|cHHz[ZM> NIK2WlYzOzh{Nkm2OC=>
OVCAR-3 Mlf0SpVv[3Srb36gRZN{[Xl? M{XiWVHjiJNzMNMg{txO MmX2NlTDqGh? MXLpcoR2[2W|IHTpd5J2eHSrb36gc4YhfGinIH3peI9kcG:wZILpZYwhfHKjboPt[Y1jemGwZTDwc5RmdnSrYXy= MYSyN|gzPjl4NB?=
OVCAR-3 NWizRXNVTnWwY4Tpc44hSXO|YYm= MkfSNgKBmzFywrFOwG0> M2PGS|I1yqCq Mm\6bY5lfWOnczDmc5Ju[XSrb36gc4YhemWjY4TpeoUhd3i7Z3XuJJNx\WOrZYO= M3vlWVI{QDJ4OU[0
OVCAR-3 NF\4S2lHfW6ldHnvckBCe3OjeR?= NFeyPYky6oDVMUFCpO69VQ>? MY[yOOKhcA>? NV3DSZNjcW6qaXLpeJMh[2WubDDh[Ihme2mxbjDhcoQhdWmpcnH0bY9v NUf0RlhYOjN6Mk[5OlQ>
MKN45 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRDBwMECxJO69\y:vbB?= NVT4fnRTOjN5OUOzOFI>
LOVO M{DXfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XyWWlEPTB;MD6xNkDPxGdxbXy= MmCxNlM4QTN|NEK=
A549 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjDdI1XUUN3ME2wMlA1KM7:Zz;tcC=> MkLSNlM4QTN|NEK=
MDA-MB-435 Mon0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnxT4VKSzVyPECuNFAyKM7:Zz;tcC=> NVzGTVNSOjN5OUOzOFI>
HepG2 M2nEdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfDT44{UUN3MEywMlAxOSEQvHevcYw> Mk\SNlM4QTN|NEK=
HL-60 NFS4dWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3LNoNKSzVyPECuNFAyKM7:Zz;tcC=> MlzsNlM4QTN|NEK=

... Click to View More Cell Line Experimental Data

Protocol

Cell Research:[5]
+ Expand
  • Cell lines: Human follicular lymphoma cell lines HF1A3, HF4.9 and HF28RA
  • Concentrations: 0 ng/mL -75 ng/mL
  • Incubation Time: 5 days
  • Method: HF1A3, HF4.9 cell viability upon the treatments is tested using double staining of cells with YO-PRO 1/PI and SYTO16/PI probes. To access cell proliferation, cells are treated with 0–100 ng/mL Brefeldin A in complete medium for 20 hours before adding 1 μCi/mL [methyl-3H]-thymidine for additional 4 hours at 37 °C. The incorporated radioactive thymidine is quantified by scintillation counting with Microbeta counter. To examine long-term effects of Brefeldin A treatment, cells are seeded at initial concentration 105 cells/mL and treated with 0-75 ng/mL Brefeldin A for up to 5 days. At the time indicated, a sample of cells is removed and viable cell number is assessed by standard Trypan Blue exclusion assay.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 4 mg/mL (14.26 mM)
Water <1 mg/mL
Ethanol <1 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 280.36
Formula

C16H24O4

CAS No. 20350-15-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

ATPase Signaling Pathway Map

Related ATPase Products

Tags: buy Brefeldin A | Brefeldin A supplier | purchase Brefeldin A | Brefeldin A cost | Brefeldin A manufacturer | order Brefeldin A | Brefeldin A distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID